Equity Profile

INDV

Indivior Pharmaceuticals, Inc.

Health CarePharmaceuticals$4.5B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing medications for addiction and mental health disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, which is vital for sustaining long-term growth.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

INDV Q2-2026 Earnings Preview

Context

Company Snapshot

Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing medications for addiction and mental health disorders. With a market cap of $4 billion, it plays a crucial role in addressing the growing need for effective treatments in these areas.

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+68.40%

Avg Stock Reaction

+9.86%

Last Quarter Recap

In Q1-2026, Indivior reported an EPS of $0.96, significantly surpassing expectations of $0.64, marking a 50.71% surprise. The stock rose 7.70% the following day, indicating positive investor sentiment.

Management Promises & Guidance

Continued focus on expanding its product portfolio.
Commitment to improving access to addiction treatments.
Plans to enhance marketing efforts for existing products.

Expectations

Wall Street Expectations

Overall, expectations for Indivior's upcoming earnings are mixed, with investors hoping for continued strong performance following recent EPS beats.

Bull Case

If Indivior maintains its track record of beating EPS estimates, it could see significant stock appreciation as investor confidence grows.

Bear Case

Conversely, any signs of slowing growth or failure to meet expectations could lead to a sharp decline in stock price, given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and will it continue the trend of exceeding expectations?

Given the company's history of beating EPS estimates, this figure will heavily influence market sentiment and stock performance.

What insights can management provide regarding revenue growth and market share in addiction treatments?

Understanding these metrics will help investors gauge the company's competitive position and future growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may underestimate Indivior's ability to sustain its growth trajectory, particularly in the addiction treatment sector, where demand is rising.

Supporting Evidence

Indivior has consistently beaten EPS estimates, suggesting strong operational execution.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Recent trends in addiction treatment highlight increasing demand, which could benefit Indivior.

Key Risk

If revenue growth significantly outpaces expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on maintaining the strong growth trajectory seen in previous quarters while addressing market challenges.

Bull Confirmed If

An EPS of $1.00 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $0.80 could signal potential issues with growth and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±21.14%

Historical Avg

±9.9%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±20.6% while INDV has averaged ±9.9% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

36.0%

Calls (1K)P/C Ratio: 0.24Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 12 of 25 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 12 of 25 faded and 13 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.9%, with a raw directional average of +0.2% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Indivior beats expectations, history suggests a potential stock increase of around +9.86%, confirming strong operational health.

In-Line / Cautious

An in-line report may lead to a muted reaction, as investors assess management's commentary for future guidance.

Miss

A miss could result in a decline, with historical data suggesting an average drop of around -9.86% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market share and competitive landscape.
3Insights into customer demand trends in addiction treatments.
4Guidance on future revenue expectations and growth strategies.
5Responses to any regulatory changes affecting the industry.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing medications for addiction and mental health disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, which is vital for sustaining long-term growth.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

INDV Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+68.40%

Avg Stock Reaction

+9.86%

Last Quarter Recap

Management Promises & Guidance

Continued focus on expanding its product portfolio.
Commitment to improving access to addiction treatments.
Plans to enhance marketing efforts for existing products.

Expectations

Wall Street Expectations

Overall, expectations for Indivior's upcoming earnings are mixed, with investors hoping for continued strong performance following recent EPS beats.

Bull Case

If Indivior maintains its track record of beating EPS estimates, it could see significant stock appreciation as investor confidence grows.

Bear Case

Conversely, any signs of slowing growth or failure to meet expectations could lead to a sharp decline in stock price, given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and will it continue the trend of exceeding expectations?

Given the company's history of beating EPS estimates, this figure will heavily influence market sentiment and stock performance.

What insights can management provide regarding revenue growth and market share in addiction treatments?

Understanding these metrics will help investors gauge the company's competitive position and future growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may underestimate Indivior's ability to sustain its growth trajectory, particularly in the addiction treatment sector, where demand is rising.

Supporting Evidence

Indivior has consistently beaten EPS estimates, suggesting strong operational execution.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Recent trends in addiction treatment highlight increasing demand, which could benefit Indivior.

Key Risk

If revenue growth significantly outpaces expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on maintaining the strong growth trajectory seen in previous quarters while addressing market challenges.

Bull Confirmed If

An EPS of $1.00 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $0.80 could signal potential issues with growth and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±21.14%

Historical Avg

±9.9%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±20.6% while INDV has averaged ±9.9% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

36.0%

Calls (1K)P/C Ratio: 0.24Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 12 of 25 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Indivior beats expectations, history suggests a potential stock increase of around +9.86%, confirming strong operational health.

In-Line / Cautious

An in-line report may lead to a muted reaction, as investors assess management's commentary for future guidance.

Miss

A miss could result in a decline, with historical data suggesting an average drop of around -9.86% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market share and competitive landscape.
3Insights into customer demand trends in addiction treatments.
4Guidance on future revenue expectations and growth strategies.
5Responses to any regulatory changes affecting the industry.